Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

Orsolya Balogh, Valentin Brodszky, László Gulácsi (), Emese Herédi, Krisztina Herszényi, Hajnalka Jókai, Sarolta Kárpáti, Petra Baji, Éva Remenyik, Andrea Szegedi and Péter Holló
Additional contact information
Orsolya Balogh: Corvinus University of Budapest
László Gulácsi: Corvinus University of Budapest
Emese Herédi: University of Debrecen
Krisztina Herszényi: Semmelweis University
Hajnalka Jókai: Semmelweis University
Sarolta Kárpáti: Semmelweis University
Petra Baji: Corvinus University of Budapest
Éva Remenyik: University of Debrecen
Andrea Szegedi: University of Debrecen
Péter Holló: Semmelweis University

The European Journal of Health Economics, 2014, vol. 15, issue 1, No 12, 109 pages

Abstract: Abstract Background Despitethe widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results Two-hundred patients were involved (females 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86 %. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p

Keywords: Psoriasis; Cost-of-illness; Quality of life; Biological treatments (search for similar items in EconPapers)
JEL-codes: I19 (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s10198-014-0599-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
Journal Article: Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres (2014)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0599-z

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-014-0599-z

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().